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Summary The value of a test for islet cell cytoplasmic 
antibodies together with a test for GAD6s antibodies 
to predict the subsequent development of diabetes 
over a period of 11.5 years was assessed in an open 
childhood population comprising 2,805 individuals. A 
single serum sample was obtained from each in- 
dividual between 1975 and 1977 and screened for islet 
cell cytoplasmic antibodies for which eight individuals 
were positive (0.29 %). During the average follow-up 
period of 11.5 years, four of eight islet cell antibody 
positive and three islet cell antibody negative in- 
dividuals developed clinical diabetes. Sera from all 
individuals, who were islet cell antibody positive and/ 
or developed iabetes (total of 11) and from 100 ran- 
domly selected control subjects were analysed for 
GAD65 antibodies. Six of eight islet cell antibody 
positive individuals were GAD65 antibody positive 
including all four who subsequently developed 
IDDM. Furthermore, one of the three islet cell anti- 
body negative individuals who developed IDDM was 
GAD65 antibody positive both in 1976 and in 1989. 
Thus, a positive test for GAD6s antibodies alone cor- 
rectly predicted iabetes in five of seven children, who 
developed the disease. Only one of the children, who 
developed iabetes was positive for insulin auto- 
antibodies and this individual was also positive for is- 
let cell cytoplasmic antibodies and GAD65 antibodies. 
One of the 100 control subjects was positive for 
GAD6s antibodies (1%). The results suggest hat a 
single GAD65 antibody test may have a higher sensi- 
tivity for predicting IDDM than a test for islet cell cy- 
toplasmic antibodies, but that a combined positive test 
for both antibodies increases the specificity for pre- 
dicting IDDM over a period of 11.5 years. [Diabeto- 
logia (1994) 37: 917-924] 
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The destruction of pancreatic beta cells, which pre- 
cedes the clinical onset of IDDM, is mediated by au- 
toimmune mechanisms [1]. The presence of islet spe- 
cific autoantibodies in the pre-diabetic period [2-4] is 
likely to reflect he ongoing autoimmune process, one 
that eventually leads to critical beta-cell depletion 
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and insulin dependency. A major goal of diabetes re- 
search is to develop immune interventions that block 
or otherwise interfere with the destruction of beta 
cells and the development of clinical diabetes. Con- 
comitant with this goal is the necessity for methods 
for early accurate identification of susceptible in- 
dividuals [5]. Antibody assays that detect early signs 
of humoral autoimmunity associated with beta-cell 
destruction are obvious candidates for this purpose. 
Furthermore, susceptibility o develop diabetes i  as- 
sociated with certain MHC-class II haplotypes [6] and 
analysis of both HLA haplotypes and autoantibodies 
provide a test of high predictive value in family 
members of IDDM patients [3, 7]. Since most new 
cases of [DDM involve individuals without a first de- 
gree relative with the disease [8, 9], predictive meth- 
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ods need to be easily applicable to analyses of the 
general population. 
The classic method to analyse islet cell auto- 
antibodies (ICA) is by immunohistology using fresh- 
frozen pancreatic sections. The ICA assay is however 
difficult to standardize [10]. A better method for a 
standardized analysis of early humoral responses in 
IDDM might involve a rapid and quantitative assay 
using a target antigen of humoral autoimmunity in
IDDM such as insulin [11], or the GAD65 autoantigen 
[12]. 
Insulin autoantibodies (IAA's) are only detected in
up to 50 % of newly-diagnosed patients and are most 
frequent in very young patients (< 5 years of age) [13]. 
IAA's alone have a limited predictive value and are 
not suitable as a marker to replace ICA's [5, 14, 15]. 
Incidence of 64 kDa or GAD65 autoantibodies in 
the pre-diabetic period and at clinical onset of IDDM 
measured by immunoprecipitation of 35S-methionine 
labelled human islet cell protein is 75-90 % [4, 16]. 
Following identification of the 64 kDa protein as the 
smaller form of the enzyme glutamic acid decarbox- 
ylase [12, 17], now called GAD65 , several assays were 
developed and standardization is now beginning (1st 
GAD antibody workshop was held under the auspices 
of the 12th International Immunology of Diabetes 
Workshop, Orlando, April 1993). GAD65 antibodies 
precede IDDM by several years and are detected 
concomitantly with, and sometimes before, ICA and 
IAA [4, 16, 18]. 
GAD6s is a cytoplasmic protein and is amongst the 
target antigens of ICA's [19, 20]. Purified GAD65 
however does not block all ICA reactivity in some sera 
[20] and the ICA reactivity is likely to involve other 
target molecules. Furthermore, sera that immuno- 
precipitate GAD6s do not always react with the pro- 
tein by immunohistology and are therefore negative in 
the ICA assay [16, 21]. In most IDDM patients, ICAs 
only stain frozen and not fixed sections of human 
pancreas. Thus, ICA epitopes are dependent on con- 
formation of the relevant antigen [22]. Similarly dia- 
betes associated epitopes in the GAD6s molecule are 
predominantly conformational nd only the sera of 
very few patients recognize a linear epitope in the 
protein [12, 19]. 
In addition to GAD6s, GAD is expressed as a sec- 
ond non-allelic form, GAD67 in neurons [23] and in rat 
and mouse beta cells [24]. Human islets only express 
the GAD6s protein [24, 25] and the incidence of 
GAD67 antibodies in IDDM is low [26, 27]. GAD67 
does not seem to have an independent role as an au- 
toantigen in IDDM. Rather this protein only seems to 
be recognized in cases where the immune response to 
GAD65 involves recognition of epitopes that cross-re- 
act in the two proteins [27]. 
Previous studies have suggested that islet ICA 
measured by immunohistology are of insufficient spe- 
cificity to serve as a single marker of susceptibility [5, 
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28, 29]. One study of the predictive value of ICA in a 
Dutch childhood population [30] without emphasis on 
families of diabetes patients, found an incidence of 
0.29 %, which is close to the incidence of IDDM in The 
Netherlands. This study used a human pancreas which 
was prepared with a very short ischaemia time result- 
ing in frozen sections that enabled ICA analyses of very 
high specificity and sensitivity [30]. All the ICA-posi- 
tive subjects had complement fixing ICA (CF-ICA) 
and the antibodies preceded the clinical onset of non- 
familial diabetes in some individuals by several years 
[30]. The predictive value of positive CF-ICA test on a 
single occasion to predict he development of IDDM in 
a subsequent 11.5-year follow-up eriod was 50 %. The 
sensitivity of CF-ICA to predict IDDM was 57 %. 
The present study analysed GAD65 autoantibodies 
in all individuals in this population who were either 
CF-ICA positive or developed IDDM during the 11.5- 
year follow-up period, as well as in 100 randomly-se- 
lected subjects who remained healthy during this pe- 
riod. Although it was not possible to analyse GAD65 
autoantibodies in the whole population with the 
methodology currently available, we have calculated 
the potential of a combined test for CF-ICA followed 
by GAD65 antibody analysis to predict diabetes in a 
childhood population at large, based on a single serum 
sample per child with a minimum follow-up of 
10 years. The study shows that the combination of a 
positive test for CF-ICA and for GAD65 antibodies 
yields a strong predictive value for subsequent devel- 
opment of IDDM in individuals who are not relatives 
of IDDM patients and is more specific than a single 
positive test for either antibody. 
Materials and methods 
Description of the population: The population studied has been 
described in detail [30]. Briefly, 4860 schoolchildren aged 5- 
19 years of age from one township in The Netherlands partici- 
pated in a longitudinal study on risk factors for cardiovascular 
and chronic diseases. The data collected included a history on 
IDDM. Serum was collected from these children between 1975 
and 1977. Serum samples of 3383 individuals were available for 
ICA analysis. In1988, aquestionnaire was sent o all subjects for 
whom family data on diabetes were available. The three criteria 
of having a complete first-degree family history of IDDM, a 
stored serum sample and an adequate r sponse to the ques- 
tionnaire by the end of an average follow-up time of 11.5 years 
were fulfilled by 2805 children. CF-ICA's and IANs were mea- 
sured in this population and their predictive value analysed [30]. 
A second serum sample was obtained in 1989 from 10 of the 
11 individuals, who were ICA positive in 1975-1977 and/or who 
developed IDDM in the interim period. 
Measurement of GAD6s antibodies using rat islets: Auto- 
antibodies to GAD65 expressed inrat islets were measured by 
immunoprecipitation of Triton X-114 (Calbiochem, San Diego, 
Calif., USA) detergent phase purified cytosolic protein fraction 
[12]. Immune complexes were analysed by SDS-PAGE using 
10 % slab gels. Gels were processed for fluorography [31]. 
Fluorograms were obtained by 2, and 4 week exposure of each 
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gel and analysed visually by three independent observers, who 
did not know the sample identity and scored positive if the 
GAD6s ct//~ doublet was visible. A quantitative stimate of 
GAD65 in positive immunoprecipitates was obtained by densi- 
tometric scanning of autoradiograms using a BioRad model 620 
Video Densitometer with 1D Analyst II and version 3.10 soft- 
ware (BioRad, Richmond, Calif., USA) and a control serum 
which is used as a positive standard for quantitative analyses of 
GAD65 autoantibodies and has an arbitrary value set at 10 [21]. 
GAD6s antibody values in other sera were calculated from in- 
tegrated peak areas by the formula: 10 • (value for unknown 
serum - value for negative control serum) / (value for positive 
control serum - value for negative control serum). The prev- 
alence of GAD6s antibodies in newly-diagnosed IDDM pa- 
tients using this method (immunoprecipitation of Triton X-114 
detergent phase purified rat islet cytosolic proteins) (n =73) is 
82.2 %. The prevalence inhealthy control individuals (n =69) is 
1.4 %. 
Measurement of GAD65 antibodies using recombinant GAD o5 
expressed in COS-cells: The eucaryotic expression vector pMT2 
(kindly donated by Dr. R. Kaufman, Genetics Institute, Bos- 
ton, Mass., USA) was used for transient expression of rat 
GAD65 in COS-7 cells. O!igonucleotide directed mutagenesis 
was used to change the sequence surrounding the translation 
initiation site of GAD65 into the Kozak consensus equence 
[32] for optimum expression in mammalian cells before sub- 
cloning into the pMT2 vector. A 2.4 kilobase cDNA fragment 
containing the coding region of rat GAD65 was released from a 
cDNA clone (kindly donated by Dr. A.Tobin, University of 
California Los Angeles, Calif., USA) by EcoR I restriction en- 
zyme digestion and inserted into the EcoR I site of pMT2. The 
resulting plasmid was named pMT2-rGAD6s-10. This clone was 
transfected into COS-7 cells (American Tissue Culture Collec- 
tion, ATCC) using lipofectamine (GIBCO/BRL Grand Island, 
New Y., USA) according to the manufacturer's instructions. 
Forty eight hours after transfection cells were labelled with 
400 ~Ci of 35S methionine (Amersham SJ-1515, Arlington 
Heights, Ill,, USA) per 10-cm plate. After labelling, cells were 
washed three times in an ice-cold harvest buffer (10 mmol/1 
Hepes/NaOH pH 7.4, 150 mmol/1 NaC1, 10 mmol/1 benzami- 
dine/HC1, 0.1 mmol/1 p-ehloromercuriphenyl sulphonic acid 
(PCMBS), and 0.1 mmol/1 phenylmethylsulphonyl fluoride 
(PMSF). All following procedures were performed at 4 ~ The 
cells were collected by scraping into 1 ml of HEAP buffer 
(10 retool/1 Hepes NaOH, pH 7.4, 1 mmol/l MgC12, 0.2 mmolfl 
pyridoxal-5-phosphate, ! retool/1 aminoethylisothiouronium 
bromide hydrobromide) containing 0.1 mmol/1 PMSF and 1% 
Triton X-114, and extracted for i hour by repeated pipetting 
through a bent pipette tip. The extract was cleared by ultra 
centrifugation at 265,000 x g for i h in a Beckman TLA-100 
ultracentrifuge with a TLA 100.3 rotor (Beckman, Fullerton, 
Calif., USA). The supernatant was subjected to a temperature 
induced TX-114 phase separation [33]. The detergent phase, 
containing the soluble amphiphilic GAD65 , was collected and 
diluted in HEMAP buffer (HEAP buffer with i mmol/1 
MgC12). Aliquots containing 200,000 cpm per immunopre- 
cipitate were precleared using normal human serum. Pre- 
cleared aliquots were incubated with test sera for 16 h in a total 
volume of 220 !~1. Immunecomplexes were isolated by incuba- 
tion for I h with protein-A Sepharose (Pharmacia, Piscataway, 
New J., USA) which had been coated with cold COS-7-cell y- 
sate to minimize non-specific absorption. Immunocomplexes 
bound to Protein-A Sepharose were washed 5 times in IMP- 
washing buffer (10 mmol/1 Hepes NaOH, pH 7.4, 150 mmol/1 
NaC1, 10 mmol/1 benzamidine/HC1, 0.5 mmol/1 methionine, 
5 mmol/1 EDTA, 0.1% bovine serum albumin) and once in au- 
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toclaved H20. Immunocomplexes were eluted from Protein-A 
Sepharose, analysed by SDS-PAGE and processed for fluoro- 
graphy. Fluorograms were obtained from a 2- and 4-week ex- 
posure of each gel, analysed for a positive GAD6~ct/fl signal and 
quantitated as described above. In addition quantitative ana- 
lyses of GAD65 on gels were performed using a model 425 
Phospor-Imager (Molecular Dynamics, Sunnyvale, Calif., 
USA) following both 1- and 3-day exposure. The results of the 
Phosphor-Imager analyses and the densitometric analyses were 
similar except hat the former measurement is linear over a 
longer range. Using the COS-cell material the prevalence of 
GAD65 antibodies is 80.8 % in newly-diagnosed IDDM pa- 
tients (n=182) and 2.2% in healthy control individuals 
(n =271). This assay ielded 100% sensitivity and 100% speci- 
ficity in the first GAD antibody workshop. 
Sera analysed for GAD65 antibodies by both assays included 
all seven individuals who developed IDDM, the four in- 
dividuals who were ICA-positive, but did not develop diabetes, 
and three control subjects. Ninety seven age-matched control 
subjects were analysed using the COS-cell assay only. 
HLA haplotyping, CF-ICA analyses, and IAA analyses: HLA 
haplotyping was performed as described by Giphart and co- 
workers [34]. The ICA assay was described earlier [30]. The 
same pancreas, which gave an unusually low background and 
high specificity in the analyses of the 1975-1977 samples [30], 
were used for analyses of the 1989 samples. The Juvenile Dia- 
betes Foundation world standard serum for ICA analyses and 
containing 80 JDF units, was positive on this pancreas up to a 
dilution of 1 : 256. Dilution of this standard serum showed a 
strict linear titration curve, 0.625 JDF units corresponding toa 
titre of 1 : 2. ICA levels in samples were expressed inreciprocal 
titres rather than JDF titres because the calculated JDF titres 
are lower than the positive range for analyses using pancreases 
of lower quality. This assay participates in the International 
Diabetes Workshops on ICA proficiency. IAA were measured 
in all seven individuals who developed IDDM, and in the four 
individuals who were ICA positive, but did not develop dia- 
betes, using both an ELISA assay [35], and a radioim- 
munoprecipitation assay [11]. Both assays participate in the 
International Diabetes Workshops on IAA proficiency. A 
positive value is defined as larger than 3 x a SD value obtained 
for 100 control individuals amongst whom none are positive in 
the radioimmunoprecipitation assay and 3.7 % are positive in 
the ELISA assay. The corresponding values for newly-diag- 
nosed IDDM patients are 15 % (n =115) and 13 % (n =84) in the 
two assays, respectively. 
Results 
The GAD65 antibody assay: The analyses of GAD65 
autoant ibodies in this study included: 1 ) im-  
munoprec ip i tat ion f the soluble hydrophobic  form of 
GAD65 partial ly puri f ied f rom rat islets [12, 17] 
(Fig. 1 A and C), and 2) immunoprec ip i tat ion f par- 
tially puri f ied membrane  and soluble forms of re- 
combinant  GAD65 expressed in COS-7 cells (Fig. 1 B 
and D). The first assay is a derivative of the standard 
immunoprec ip i tat ion assay using GAD65 expressed in 
islet cells [4, 21] but uses only the hydrophobic  soluble 
fraction of islets. Since very few cytosolic proteins in 
rat islets, except GAD65 , are hydrophobic,  the use of 
this fract ion results in a very low background in im- 
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Fig.1 (A-D). Analysis of GAD65 autoantibodies by im- 
munoprecipitation. GAD6s autoantibodies were measured in a 
single serum sample drawn from subjects at baseline (1975- 
1977) (panels A-C) or in 1989 (panel D). Subjects 1-8 were ICA 
positive, subjects 9-14 were ICA negative. Subjects 1-4 and 9- 
11 developed IDDM 1.8-7.1 years following the serum sam- 
piing. Subjects 12and 13 were healthy ICA-negative children. 
A, Short exposure of a fluorogram ofimmunoprecipitates of rat 
islet cell GAD65 on an X-ray film 
B, Short exposure of a fluorogram of immunoprecipitates of 
COS-7 cell GAD65 on a Phosphor-Imager 
C, Long exposure of the fluorogram in panel A 
D, Short exposure of a fluorogram of immunoprecipitates of 
COS-7 cell GAD65 on an X-ray film 
munoprecipitates. Both methods are equally sensitive 
in detecting GAD65 autoantibodies in low-high titre 
sera. However, the first method is more sensitive for 
analyses of very low titre sera, because it has a better 
signal to noise ratio and allows specific detection of 
very low levels of the characteristic ~ and fi doublet of 
GAD65 in immunoprecipitates [31] by long exposure 
of autoradiograms. This enhanced sensitivity was 
necessary for detection of GAD65 antibodies in the 
baseline serum from subject number 11 (Fig. 1 C) and 
the 1989 serum from subject number 4 (Fig. 2) in long 
exposure of fluorograms. By comparison the COS-7 
cell assay did not detect a GAD65 signal above back- 
ground in immunoprecipitates with those two samples 
after long exposures. Both assays however detected 
GAD6s antibodies in the same individuals in either 
earlier (subject number4) or later (subject num- 
ber 11) samples (Figs. 1 and 2, Table 1). 
Prevalence of IDDM in the follow-up eriod: Seven 
children developed IDDM, which gave a cumulative 
incidence of IDDM during an average follow-up peri- 
od of 11.5 years of 0.25 % (7 of 2805; CL: 0.10-0.51%). 
None of those seven children had a first degree family 
member with IDDM or NIDDM. 
Prevalence of CF-ICA, GAD65 antibodies, and IAA in 
1975-1977: Eight of 2,805 (0.29 %; CL: 0.12-0.56 %) 
children (numbers 1-8, Table 1) were positive for CF- 
ICA at the baseline timepoint between 1975-1977. 
Four of these (numbers 1-4. Table 1) were among the 
seven who developed IDDM during the follow-up 
period. Sera from the seven individuals who devel- 
oped diabetes as well as from the other four ICA- 
positive individuals were assayed for GAD6s auto- 
antibodies (Fig. 1 A-C: Table 1) and IAA. Six of the 
eight ICA-positive individuals (number 1-4. 5 and 8. 
Fig. 1A-C; Table 1) were positive, including all four 
who subsequently developed IDDM. One of those in- 
dividuals (number 3), was the only IAA-positive in- 
dividual by the ELISA assay whereas none were posi- 
tive by the radio immunoprecipitation assay. 
Among the three ICA-negative children who de- 
veloped IDDM during the follow-up period, two 
(number 9 and 10. Fig. 1 A-C; Table 1) were also neg- 
ative for GAD65 antibodies in the serum sample col- 
lected between 1975-1977. One subject (number 11, 
Fig. 1, Table 1) was scored negative for GAD65 anti- 
bodies based on a short exposure of fluorograms of 
rat islet immunoprecipitates and COS-7 cell im- 
munoprecipitates (Fig. 1 A). However, prolonged ex- 
posure of rat islet immunoprecipitates clearly re- 
vealed that this serum immunoprecipitated th  char- 
acteristic a and fi doublet of the GAD65 autoantigen 
(Fig. 1 C). Amongst 100 healthy ICA-negative sub- 
jects included in the GAD65 antibody analyses, one 
individual, a 16-year-old female, was GAD65-anti- 
body-positive (GAD65 antibody index 3.5). 
GAD65 antibody status 12-13 years after the initial 
sampling: In 1989 sera were collected from all the 
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Fig.2. Longitudinal analyses of GAD65 autoantibodies (open 
circles) and ICA (closed circles) in subjects 3 (top panel) and 4 
(lower panel). ICA titres are converted to JDF units. Arrows 
indicate onset of IDDM 
eight subjects who were ICA-positive at baseline 
(number 1-8) and from two of the ICA-negative sub- 
jects (number 10 and 11) who had developed IDDM. 
Subject number 9was not available for testing in 1989. 
Sera were assayed for GAD65 autoantibodies and ICA 
(Fig.lD, Table 1). The ICA and GAD65 antibody- 
positive individuals who had developed IDDM had 
either become antibody negative or decreased sig- 
nificantly in titre. The ICA-negative, GAD65 anti- 
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body-positive individual (number 11) had a stronger 
GAD65 immunoreactivity in 1989 than in 1977 
(Fig. 1 D, Table 1). The two individuals who were ICA/ 
GAD65 antibody-positive at the baseline timepoint 
(number 5 and 8) but did not develop IDDM during 
the observation period, were still ICA and GAD65 an- 
tibody positive in 1989, which was 12 and 13 years lat- 
er, respectively. Neither of those individuals has a first 
degree family member with IDDM or NIDDM. 
However, a niece to subject number 8 had a clinical 
onset of IDDM in 1989. Subject number 6 was still 
GAD65 antibody-negative and had also become ICA- 
negative in 1989. Subject number 7 was still GAD65 
antibody-negative and ICA-positive in 1989. Subject 
number 10 was ICA and GAD65 antibody-negative 
both at baseline and in 1989 which was 1.8 years be- 
fore and 11.9 years after clinical onset of IDDM, re- 
spectively. The positive control individual had no 
family history of IDDM. She did not consent o an 
additional serum sampling to test whether the GAD65 
antibodies had persisted over several years. 
Longitudinal analyses of lCA and GAD antibodies in 
two subjects: Two girls (subjects number 3and 4) also 
participated in a cohort study for general health risk 
factors. Each developed IDDM during the period of 
this study. Both were reexamined every 12 months. 
ICA and GAD65 antibody titres were retrospectively 
analysed and compared in the sequential sera (Fig. 2). 
Subject 3 remained weakly positive for GAD65 anti- 
bodies throughout the 11-year observation period, 
which included 5years following the clinical onset of 
IDDM. Subject 4 showed acontinual decrease from a 
high GAD65 antibody immunoreactivity during the 
13-year observation period. She was weakly positive 
in the last sample, which was obtained 9years follow- 
ing clinical onset of IDDM. A similar pattern was ob- 
served for ICA. 
Table 1. Summary of autoantibody and HLA-analyses inindividuals which were either positive for islet cell cytoplasmic antibodies 
(ICA) at baseline and/or developed diabetes during an average of 11.5 year observation period 
Subject Age at Age at Interval HLA ICA 
number/sex baseline diagnosis (years) 
GAD65 autoantibodies a 
DR DQw 1975-77 1989 1975-77 1989 
ICCA + -+ diabetes 
1 M 6.1 12.4 6.3 2,3 2,6 2 Neg 2.9 Neg 
2M 7.5 12.4 4.9 3 2 32 Neg 4.0 Neg 
3F 9.2 16.3 7.1 3,4 2,8 16 8 1.8 1.6 
4F 15.4 19.6 4.2 3,4 2,8 4 Neg 9.9 0.6 b 
ICCA + --+ healthy 
5 M 7.4 3,4 2,8 32 16 14.9 13.9 
6F 7.6 2 6 4 Neg Neg Neg 
7 M 14.7 1, w6 5,6 32 64 Neg Neg 
8 M 18.2 1, w6 5,6 16 32 14.2 12.0 
ICA-  --+ diabetes 
9 M 5.1 12.3 7.5 NA NA Neg NA Neg NA 
10 M 12.4 14.2 1.8 4, w6 6,8 Neg Neg Neg Neg 
11 M 12.7 16.2 3.5 1,5 5,7 Neg Neg 0.5 b 3.2 
a The quantitative alues are based on Phosphor-Imager analyses except for those marked by b, which are densitometric values 
922 
Sensitivity of individual and combined assays to predict 
IDDM: The sensitivity of a combined antibody assay 
positive for both ICA and GAD65 antibodies in a sin- 
gle sample to predict IDDM in the seven children who 
had a clinical onset during the follow-up period was 
57 % (4 of 7; CL: 18-90 %) or the same as for ICA 
alone. The sensitivity of a GAD65 antibody assay alone 
to predict IDDM in the seven children was 71% (5 
of 7; CL: 29-96 %). 
The sensitivity of a combined assay positive for 
both ICA and IAA in a single sample to predict IDDM 
in the seven children, who had a clinical onset during 
the follow-up period was 14 % (1 of 7; CL: 1-53 %) or 
the same as the sensitivity of IAA antibodies alone 
and several fold lower than the sensitivity of the ICA 
and GAD65 antibody assays alone. 
Predictive value of ICA combined with GAD65 auto- 
antibodies: The lack of GAD65 antibody data for all 
but 111 of the 2.805 children constituting this study 
base excludes the calculation of a positive and a nega- 
tive predictive value and a specificity for GAD65 anti- 
bodies alone [36, 37]. However, these parameters can 
be calculated for a combined ICA and GAD65 anti- 
body assay. Thus, the probability of a child acquiring 
IDDM within 10 years if both autoantibodies were 
positive at baseline (positive predictive value) was 
67 % (4 of 6; CL: 22-96 %) as compared to 50 % (4 of 8; 
CL: 16-84 %) for ICA alone. The probability of ab- 
sence of clinical IDDM among subjects not positive 
for both ICA and GAD65 antibodies (negative pre- 
dictive value) was 99.89 % (2796 of 2799; CL: 99.68- 
99.98) or the same as for ICA alone (2794 of 
2797=99.89 %; CL: 99.69-99.98). The specificity of a 
test positive for both ICA and GAD65 antibodies to 
predict IDDM within 10 years was 99.93 % (2796 of 
2798; CL: 99.74-99.99) as compared to 99.86 % (2794 
of 2798; CL: 99.63-99.96) for ICA alone. 
Predictive value of ICA combined with IAA: The pos- 
itive predictive value for a combined ICA and IAA 
assay was 100 % (1 of 1), which was higher than for a 
combined assay for ICA and GAD65 antibodies. Simi- 
larly the specificity of the combined assay was i00 % 
(2798 of 2798; CL: 99.86-100.00 %). The probability of 
absence of clinical IDDM among subjects not positive 
for both ICA and IAAwas 99.79 % (2798 of 2804; CL: 
99.53-99.92 %) compared to the negative predictive 
value for ICA alone and ICA combined with GAD65 
antibodies of 99.89 %. 
HLA-tissue typing: HLA DR and DQ haplotypes are 
shown in Table 1. Subjects 1-5 and 10 were HLA DR3 
and/or DR4 positive. All the HLA DR4-positive sub- 
jects had the DQw8 (DQBI*0302) allele which is 
present in 95 % of DR4-positive IDDM patients vs 
50 % of DR4-positive control subjects [6, 38]. Sub- 
jects 7, 8 and 11 had the DR1, DQw5 (DQBI*0501) 
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haplotype, which is associated with a weakly increased 
risk of IDDM [38]. Subject 6 was positive for the 
HLA-DR2, DQw6 (DQBI*0602) haplotype, which is 
negatively associated with IDDM [39]. Subject num- 
ber 9 was not available for HLA-typing. The positive 
control individual did not consent to HLA-typing. 
Discussion 
We have assessed the predictive value of a combined 
assay for ICA and GAD65 antibodies in a single serum 
sample and with an average follow-up of 11.5 years in 
a low-risk childhood population. The low prevalence 
of ICA in the 2805 individuals analysed in this study 
(0.29 %) has been attributed to the high specificity and 
sensitivity of the pancreas used for the ICA analyses 
[30]. Other studies have reported values of 0.35 % 
[40], 1.05 % [41], 2.8 9/0 [42], 3.0 % [43], and 4.1 9/0 [44] 
respectively in childhood populations. The results 
presented here suggest hat even compared to un- 
usually specific ICA measurements alone, ICA anal- 
yses supplemented with GAD6s autoantibody analysis 
are likely to have increased specificity in predicting 
IDDM. Of a normal low-risk population of 
2805 children who represented the study base for 
these analyses, four children would be incorrectly 
predicted to become diabetic in a 10-year follow-up by 
a single positive test for CF-ICA alone. This number 
was decreased to two subjects by requiring both CF- 
ICA positivity and GAD6s autoantibody positivity. 
Although analysis of GAD65 antibodies in 2805 sera 
was not possible by the current methodology, the pre- 
sence of GAD65 antibodies in 1 of 100 individuals 
randomly selected from among the ICA-negative 
subjects, who did not develop IDDM. confirms earlier 
data on the prevalence of these antibodies in healthy 
individuals [45]. A prevalence of 1% is however 3-4 
fold higher than the cumulative incidence of IDDM in 
The Netherlands uggesting that a positive test for 
GAD65 antibodies alone, measured by current meth- 
ods, is not sufficient o accurately predict he clinical 
onset of disease within a period of 11.5 years. 
This study has confirmed the early appearance of
GAD65 autoantibodies in a non-familial study. The 
antibodies were detected in five individuals in a single 
serum sample obtained 3.5-7 years before clinical on- 
set of IDDM. None of these subjects had a first-degree 
family member with IDDM or non-IDDM. Amongst 
the three CF-ICA-negative individuals who devel- 
oped IDDM, one was positive for GAD65 antibodies 
at baseline and in 1989, which was 3.5 years before and 
9.5 years after clinical onset, respectively. The in- 
crease in sensitivity of the single GAD65 antibody test 
compared to the double antibody test was however 
counterbalanced by a decrease in specificity. It is pos- 
sible that the predictive value of a test for GAD65 au- 
toantibodies alone can be increased by introducing 
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different GAD6s antibody specificities. Recent studies 
have identified conformational epitopes associated 
with IDDM [19], linear epitopes pecific for patients 
with stiff-man syndrome [12], and a linear epitope as- 
sociated with protection against disease [46] in the 
GAD65 molecule. Assays that distinguish GAD65 an- 
tibodies of different epitope specificity may therefore 
be the next candidates for predictive tests. Alter- 
natively, acombination ofa test for GAD6~ antibodies 
for high sensitivity and early detection, and a test for 
antibodies that appear late in beta-cell destruction, 
and may be indicative of massive loss of beta cells, may 
provide a better predictive value. A candidate for the 
latter test are the 37 kDa antibodies described by 
Christie et al. [47]. Finally since beta-cell destruction 
in humans is likely to be T-cell mediated as in the ani- 
mal models, [1] and antibodies may not have a direct 
pathogenic role, the predictive value of antibody tests 
may always have the limitations of an indirect param- 
eter. It is certainly conceivable that an autoimmune 
response induced to an antigenic epitope in a partic- 
ular HLA-background is dominated by cytotoxic 
T cells and massive beta-cell destruction whereas the 
response to other epitopes in the same molecule in the 
same or different HLA-haplotype is restricted to an- 
tibodies and compatible with an intact or only minor 
loss of beta-cell mass. 
In the absence of a direct est for beta-cell destruc- 
tion, a combination of a positive test for CF-ICA and 
GAD6s autoantibodies together with HLA-typing 
may provide the most accurate predictive test cur- 
rently available. In this regard it is notable however 
that subject number 5, who has been positive for CF- 
ICA and GADt~ antibodies for more than 12 years, 
has the HLA-DR3, DQw2 and DR4,DQw8 haplo- 
type, which confers the highest known relative risk of 
IDDM [7]. Thus, even this high risk MHC allele in 
conjunction with both CF-ICA and GAD65 auto- 
antibodies i still not sufficient to rapidly induce the 
onset of IDDM. 
Both CF-ICA, IAA, and GAD65 antibodies were 
absent at baseline in two individuals who later devel- 
oped IDDM. It is not known whether antibodies 
never developed in these individuals or whether anti- 
body-positive periods were missed by the single sam- 
pling at baseline. Population studies employing reg- 
ular sampling of sera over 10-20 years are clearly 
needed to assess the full value of antibody testing in 
predicting IDDM, and in particular to assess whether 
some individuals mount an autoimmune response 
which is restricted to T cells, or alternatively, experi- 
ence a beta-cell destruction which is not of auto- 
immune aetiology. 
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